Huntington's disease (HD) is a monogenic, autosomal‐dominant neurological disorder characterized by motor, cognitive, and behavioral symptoms that have a devastating effect on the life of the person affected.1 Symptoms typically begin in early adult life and the disease is usually fatal, with a median survival rate of 18 years after motor onset.2 Despite the disease being identifiable by a single genetic marker – an expanded cytosine‐adenine‐guanine (CAG) repeat in the huntingtin gene3 – an effective disease‐modifying treatment has yet to be found. This evidence concerns the gene HTT and Huntington disease.